Transitioning the Molecular Tumor Board from Proof of Concept to Clinical Routine: A German Single-Center Analysis

The repertoire of mutational signatures in human cancer

(2020) Ludmil B. Alexandrov et al.   NATURE

2019 FDA drug approvals

(2020) Asher Mullard   NATURE REVIEWS DRUG DISCOVERY

The mutational constraint spectrum quantified from variation in 141,456 humans

(2020) Konrad J. Karczewski et al.   NATURE

Analysis of mutational signatures with yet another package for signature analysis

(2020) Daniel Hübschmann et al.   GENES CHROMOSOMES & CANCER

2018 FDA drug approvals

(2019) Asher Mullard   NATURE REVIEWS DRUG DISCOVERY

Variant classification in precision oncology

(2019) Jonas Leichsenring et al.   INTERNATIONAL JOURNAL OF CANCER

Defective homologous recombination DNA repair as therapeutic target in advanced chordoma

(2019) Stefan Gröschel et al.   Nature Communications

1192OAssociation of tumour mutational burden with outcomes in patients with select advanced solid tumours treated with pembrolizumab in KEYNOTE-158

(2019) A Marabelle et al.   ANNALS OF ONCOLOGY

Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study

(2019) Aurelien Marabelle et al.   JOURNAL OF CLINICAL ONCOLOGY

The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors

(2019) Andrew A. Davis et al.   Journal for ImmunoTherapy of Cancer

Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial

(2019) Joaquin Mateo et al.   LANCET ONCOLOGY

Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer

(2018) Matthew D. Hellmann et al.   CANCER CELL

Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study

(2018) John D. Hainsworth et al.   JOURNAL OF CLINICAL ONCOLOGY

HER kinase inhibition in patients with HER2- and HER3-mutant cancers

(2018) David M. Hyman et al.   NATURE

Time to progression ratio in cancer patients enrolled in early phase clinical trials: time for new guidelines?

(2018) Sarah Watson et al.   BRITISH JOURNAL OF CANCER

Der prädiktive Wert der PD-L1-Diagnostik

(2018) H.-U. Schildhaus   PATHOLOGE

A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer

(2017) Paz Polak et al.   NATURE GENETICS

BRAF/MEK double blockade in refractory anaplastic pleomorphic xanthoastrocytoma

(2017) Denis Migliorini et al.   NEUROLOGY

Tumor Mutational Burden and Response Rate to PD-1 Inhibition

(2017) Mark Yarchoan et al.   NEW ENGLAND JOURNAL OF MEDICINE

DGIdb 3.0: a redesign and expansion of the drug–gene interaction database

(2017) Kelsy C Cotto et al.   NUCLEIC ACIDS RESEARCH

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

(2017) Dung T. Le et al.   SCIENCE

Accelerating Discovery of Functional Mutant Alleles in Cancer

(2017) Matthew T. Chang et al.   Cancer Discovery

High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial

(2017) Christophe Massard et al.   Cancer Discovery

ATM mutations and E-cadherin expression define sensitivity to EGFR-targeted therapy in colorectal cancer

(2017) Anna-Lena Geißler et al.   Oncotarget

The time to progression ratio: a new individualized volumetric parameter for the early detection of clinical benefit of targeted therapies

(2016) G. A. Cirkel et al.   ANNALS OF ONCOLOGY

Randomized phase II trial comparing molecularly targeted therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer: Cross-over analysis from the SHIVA trial

(2016) L. Belin et al.   ANNALS OF ONCOLOGY

dbNSFP v3.0: A One-Stop Database of Functional Predictions and Annotations for Human Nonsynonymous and Splice-Site SNVs

(2016) Xiaoming Liu et al.   HUMAN MUTATION

Spatio-temporal mutation profiles of case-matched colorectal carcinomas and their metastases reveal unique de novo mutations in metachronous lung metastases by targeted next generation sequencing

(2016) Valentina Kovaleva et al.   Molecular Cancer

Limits to Personalized Cancer Medicine

(2016) Ian F. Tannock et al.   NEW ENGLAND JOURNAL OF MEDICINE

COSMIC: somatic cancer genetics at high-resolution

(2016) Simon A. Forbes et al.   NUCLEIC ACIDS RESEARCH

Clinical benefit of a precision medicine based approach for guiding treatment of refractory cancers

(2016) Milan Radovich et al.   Oncotarget

Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial

(2016) Tracy L. Stockley et al.   Genome Medicine

Olaparib Monotherapy in Patients With Advanced Cancer and a GermlineBRCA1/2Mutation

(2015) Bella Kaufman et al.   JOURNAL OF CLINICAL ONCOLOGY

Prospective Clinical Study of Precision Oncology in Solid Tumors

(2015) Davendra P. S. Sohal et al.   JNCI-Journal of the National Cancer Institute

Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial

(2015) Christophe Le Tourneau et al.   LANCET ONCOLOGY

Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity

(2015) Matthew T Chang et al.   NATURE BIOTECHNOLOGY

Prospective Clinical Study of Precision Oncology in Solid Tumors

(2015) Davendra P. S. Sohal et al.   JNCI-Journal of the National Cancer Institute

Trimmomatic: a flexible trimmer for Illumina sequence data

(2014) Anthony M. Bolger et al.   BIOINFORMATICS

Salvage therapy with BRAF inhibitors for recurrent pleomorphic xanthoastrocytoma: a retrospective case series

(2013) Marc C. Chamberlain   JOURNAL OF NEURO-ONCOLOGY

Signatures of mutational processes in human cancer

(2013) Ludmil B. Alexandrov et al.   NATURE

ClinVar: public archive of relationships among sequence variation and human phenotype

(2013) Melissa J. Landrum et al.   NUCLEIC ACIDS RESEARCH

STAR: ultrafast universal RNA-seq aligner

(2012) Alexander Dobin et al.   BIOINFORMATICS

VarScan 2: Somatic mutation and copy number alteration discovery in cancer by exome sequencing

(2012) D. C. Koboldt et al.   GENOME RESEARCH

Improving the Assessment of the Outcome of Nonsynonymous SNVs with a Consensus Deleteriousness Score, Condel

(2011) Abel González-Pérez et al.   AMERICAN JOURNAL OF HUMAN GENETICS

Control-FREEC: a tool for assessing copy number and allelic content using next-generation sequencing data

(2011) Valentina Boeva et al.   BIOINFORMATICS

dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions

(2011) Xiaoming Liu et al.   HUMAN MUTATION

Control-free calling of copy number alterations in deep-sequencing data using GC-content normalization

(2010) Valentina Boeva et al.   BIOINFORMATICS